Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
Mankind Pharma develops oral anti-obesity drug, eyes global breakthrough
If successful, Mankind’s drug would be the first oral small-molecule alternative, offering a pill-based treatment.